## Vaccine recommendations for immunocompetent older adults

Vaccine		Age				
		50-59	60-64	65-74	≥ 75	
New since 2020	COVID-19	1 dose of the most updated formula*				
	Respiratory syncytial virus (RSV)	Not indicated	1 dose, depending on risk factors**		1 dose	
	Pneumococcus <sup>†</sup> Pneumococcal conjugate, PCV20 or PCV21		pending on 1 do		ose	
Unchanged schedule	Influenza	1 dose annually				
	Zoster	2 doses, 2-6 months apart				
	Tetanus / Pertussis	1 dose, then Td or Tdap booster every 10 years				

<sup>\*</sup>Recommendations here are for Moderna and Pfizer/BioNTech products; one additional dose is required for the Novavax product if unvaccinated. \*\*Risk factors described at AlosaHealth.org/Immunizations. 
†PCV15 and pneumococcal polysaccharide (PPSV23) can be used as an alternative if PCV20 or PCV21 are unavailable.

**Reference:** Centers for Disease Control and Prevention. Adult Immunization Schedule by Age (Addendum updated June 27, 2024). Nov 16, 2023; www.cdc.gov/vaccines/schedules/hcp/imz/adult.html. Accessed July 8, 2024.

## **Usual Medicare coverage immunizations**

Vaccine	Clinician office (Medicare Part B)	Pharmacy (Medicare Part D)
Influenza	<b>√</b>	<b>✓</b>
Respiratory syncytial virus (RSV)	X	<b>✓</b>
Pneumococcal PCV15, PCV20, PCV21, PPSV23	<b>✓</b>	X
COVID-19	<b>√</b>	<b>√</b>
Tetanus / Pertussis	X	<b>√</b>
Zoster	X	<b>√</b>

Newly approved vaccinations may not be immediately covered by all Medicare plans. Non-Medicare patients may receive vaccinations in different settings and may be subject to copays.







Balanced information for better care

These are general recommendations only; specific clinical decisions should be made by the treating clinician based on an individual patient's clinical condition. These materials were made possible by the PACE Program of the Department of Aging of the Commonwealth of Pennsylvania. Links to references can be found at AlosaHealth.org.